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Zinc in Depression: From development to treatment: A comparative/ dose response meta- 1 
analysis of observational studies and randomized controlled trials 2 
ABSTRACT 3 
Background: A previous meta-analysis suggested that zinc status may be linked to depression 4 
status. However, it remains unclear whether zinc status can predict the risk of depression 5 
development, or whether the monotherapy of zinc is superior to the combination of zinc 6 
supplementation and antidepressant medications in the treatment of depression. Therefore, this 7 
meta-analysis aimed to clarify the impact of zinc status and supplementation on depression 8 
development and status across all available evidence. 9 
Methods: PubMed, EMBASE, Scopus, and ISI web of science were searched, up to 14 May 2020, 10 
for relevant publications. Pooled relative risks (RRs) with 95% confidence intervals (CI) in 11 
observational studies, and mean and standard deviation (SD) for the change in depression score in 12 
RCTs were calculated using a random-effects model. 13 
Results: The meta-analysis of RCTs indicated that zinc supplementation significantly lowered 14 
depressive symptom scores of depressed patients [weighted mean difference (WMD = −4.15 point; 15 
95% CI: −6.56, −1.75 point; P < 0.01)], and the improvement in depression status occurred only 16 
when zinc supplementation was prescribed as a monotherapy. The cohort studies showed that the 17 
highest level of zinc intake was associated with a 28% reduced risk of depression (RR: 0.66; 95% 18 
CI: 0.50, 0.82; I2 = 13.90). Dose-response analyses revealed a significant non-linear effect of 19 
baseline mood status on depression score. 20 
Conclusion: Current evidence from observational studies and RCT’s supports the potential 21 
benefits zinc to reduce the risk of, and alleviate, depression. However, further trials are needed to 22 
confirm the beneficial effect of zinc as a monotherapy versus adjunctive therapies. 23 
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The monoamine hypothesis, accepted as the most common hypothesis with regard to the 29 
pathophysiology of depression [1, 2], has led to the development of almost all currently used 30 
antidepressant drugs [3], including selective serotonin reuptake inhibitors (SSRIs) or serotonin- 31 
norepinephrine reuptake inhibitors (SNRIs) [3, 4]. However, remission is achieved in only one- 32 
third of patients after treatment with SSRIs [3]. Antidepressants have latency of response [1, 5], 33 
indeed, some evidence suggests that the monoamine hypothesis may be inadequate and emphasizes 34 
the need for creating alternative, preventative and treatment, approaches to antidepressant 35 
medication [1, 4]. Micronutrients currently represent the most prominent and valid alternate to 36 
monoamine-based antidepressant medicine, as introduced in the "nutritional psychiatry 37 
hypothesis" [6, 7].  38 
Zinc is a micronutrient to have received much attention, due to its’ possible role in depression 39 
[8]; for instance, zinc dysregulation in the hippocampus, amygdala, and the cerebral cortex is 40 
purportedly linked to the pathophysiology of depression [9-13]. Furthermore, dysregulation of 41 
brain zinc status is reported in many psychiatric and neurological disorders, such as 42 
schizophrenia [14], mood disorders [15], Parkinson’s [16], and Alzheimer’s disease [16]. 43 
Regulation of zinc levels within the brain may have a critical therapeutic role in neuropsychiatric 44 
diseases [11]. Indeed, support for this hypothesis originates from studies’ reporting that zinc 45 
deprivation can induce depressive-like behavior, which can be effectively reversed by zinc 46 
supplementation [17, 18]. Furthermore, it is conceivable that zinc could be used to enhance the 47 
antidepressant effects of drugs belonging to the SSRI group [19, 20]. Considering this viewpoint, 48 
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a connection between zinc and depression is highly probable. Concordantly, a meta-analysis of 49 
seventeen observational studies reported that serum zinc concentration was lower in depressive 50 
patients, as compared to a healthy population, whilst the severity of depression status was related 51 
to the degree of zinc deficiency [21]. A recent meta-analysis, by Li et al., reported an inverse 52 
association between zinc status and risk of depression; however, this study exclusively 53 
considered zinc intake [22]. Several meta-analyses have investigated the effect of zinc 54 
supplementation on depression status, however, these studies mainly focused on the efficacy 55 
adjunctive zinc therapy [23-25]. Notwithstanding the previous investigations, it is unclear 56 
whether the monotherapy of zinc is superior to the combination of zinc supplementation and 57 
antidepressant medications in depression, furthermore sources of heterogeneity are currently 58 
unclear. Therefore, this meta-analysis sought to clarify the impact of zinc status and 59 
supplementation on depression development and status across all available observational and 60 
RCTs, and to conduct a dose-response analysis to investigate whether the effect of zinc 61 
supplementation on depression symptoms had non-linear association.  62 
Materials and Methods: 63 
 64 
The present systematic review and meta-analysis was conducted based on the Preferred Reporting 65 
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [26]. We also followed 66 
the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines for reporting 67 
the meta-analysis of observational studies [27]. The review protocol was registered with the 68 
Prospero International Prospective Register of Systematic Reviews (http://www.crd. 69 
york.ac.uk/PROSPERO registration number CRD42018108150) 70 
Search strategy 71 
PubMed, EMBASE, Scopus, and ISI web of science, were searched for relevant medical literature, 72 
without language or publication date restriction, up to 14 May2020. The keywords used in our 73 
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search strategy were “zinc” and “depression”. Further details about the search strategy in the 74 
aforementioned databases are provided in Supplementary Table 1. Reference lists of previous 75 
review papers that investigated the association between zinc and depression were also checked for 76 
any additional studies that were not identified by the database searches. All titles and abstracts 77 
were screened by two authors (SY and P Sh) to find eligible studies.  78 
Inclusion criteria 79 
All publications with cross-sectional, cohort, case-cohort, and nested case-control designs, as well 80 
as follow-ups of randomized controlled trials (RCTs) that described zinc-depression association, 81 
were included. RCTs, as well as observational studies, were included if; 1) they were original 82 
studies, 2) they reported depression score as outcome, 3) zinc was used as the intervention 83 
approach (RCTs) or exposure/risk factor in observational studies, 4) the study was conducted in a 84 
general adult population. If multiple studies were published on the same population, then the most 85 
recent, with most complete reports, were included. RCT studies that addressed the effect of zinc 86 
combined or compared with other vitamins and minerals were excluded. Studies were also 87 
excluded if they were conducted in lactating/pregnant women. 88 
Data extraction 89 
The following data from eligible studies were extracted: the name of first author, year of the 90 
publication, country, study design, number of participants, depression score and tools, sex, length 91 
of study or follow-up, type/dose of zinc used in the RCTs design and the method of zinc assessment 92 
in observational studies, use of antidepressant medication, and list of adjusted variables in 93 
observational studies. Data extraction and study selection were conducted independently by two 94 
investigators (SY, MA). In instances of divergence, a third reviewer (SS) was consulted.  95 
  96 
Quality of evidence: 97 
The Cochrane collaboration tool was used to assess the quality of the RCTs studies. This tool 98 
categorizes the quality of studies into two levels: low quality, defined as a Cochrane collaboration 99 
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score lower than five points, and high quality defined as a score ≥ 5 [28]. A modified version of 100 
the Newcastle Ottawa Scale (NOS), designed for nonrandomized studies, was used to quality 101 
assessment of the eligible observational studies [29]. This scale has a range of 0 to 9, where studies 102 
with scores equal 9 points represents the highest quality. 103 
  104 
Statistical analysis 105 
We conducted separate analyses for RCTs and observational studies, in order to address the 106 
fundamental differences between these types of study designs. For RCTs studies, our outcome of 107 
interest was the difference in pre to post-intervention changes in depression scores with control 108 
groups. If changes were not reported, the mean and SD of changes from baseline to follow-up 109 
were estimated for each intervention and control group using the calculated correlation 110 
coefficient for studies that reported the baseline, after follow-up, and change values [r=0.67] [20, 111 
30, 31]. We calculated the mean difference and its corresponding standard error (SE) as the 112 
effect size to perform the meta-analysis, because the depression score values were reported in the 113 
same scales (Beck questionnaire). The random-effects model was used to pool the data from 114 
included studies when the extent of inconsistency (I2) was > 50 % [32]. Sensitivity analyses were 115 
also conducted to evaluate the impact of individual studies on overall pooled estimates and 116 
heterogeneity. We evaluated the potential sources of heterogeneity with the following subgroup 117 
analyses: depression scale (Beck compared with Hamilton questioner), study duration (<12 118 
weeks compared with ≥12 weeks), and adjunctive therapy (with or without anti-depressive agent 119 
therapy). Moreover, a meta- regression analysis was conducted to check the effect of age, 120 
baseline depression score, dose of zinc supplementation, and the study duration (as a continues 121 
form) on predicting WMD of depression status. The potential non-linear effects of the age of 122 
participants and baseline mood status on depression score was investigated using fractional 123 
polynomial models for RCTs [33] . 124 
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For observational studies, the meta-analysis was performed by combining the multivariable- 125 
adjusted odds ratios (ORs) and their 95% confidence intervals (95% CIs) for comparing the 126 
prevalence or the incidence of depression between groups with the highest and lowest zinc 127 
status. Relative risks (RRs) were considered as ORs when used in the meta-analysis. The effect 128 
size was pooled based on the random-effects model using the Der Simonian–Laird method, 129 
which incorporated both within and between-study variability [34]. Statistical heterogeneity was 130 
assessed using Cochran’s Q test and I2 statistic [35]. Publication bias was evaluated by Egger’s 131 
regression asymmetry test [36] and Begg’s adjusted rank correlation test [37]. The meta-analysis 132 
was performed with STATA software (version 13.0; Stata Corp), and P values less than 0.05 133 
were considered statistically significant. 134 
RESULTS 135 
Literature search and study characteristics. A total of thirteen observational studies (9 cross- 136 
sectional studies and four cohort studies) [38-49], and eight RCTs [19, 20, 30, 31, 50-53] met the 137 
inclusion criteria for meta-analysis, from the 4245 articles initially retrieved from the electronic 138 
search. The selection process of included studies is detailed in Supplementary Figure 1 and 139 
Supplementary Figure 2. 140 
RCT studies. RCT studies were conducted between 2003 and 2018 [19, 20, 30, 31, 50-53].  These 141 
studies provided data for 319 participants (intervention = 159, control= 160). Trial durations 142 
ranged from 2 to 12 weeks; all studies conducted in both sexes. Three RCT studies investigated 143 
the effect of zinc supplementation compared to placebo [51, 30, 31], whilst in five RCT studies, 144 
the adjunctive effect of zinc versus antidepressant drugs was evaluated [50, 19, 20, 52, 53]. Most 145 
RCTs were conducted in Iran [20, 30, 31, 50-52], and the remainder (n=2) were conducted in 146 
Poland [19, 53]. The participants were depressed-only [19, 20, 31, 50-53] in most included studies, 147 
except one study, which was conducted on a mixed population (depressed and non-depressed 148 
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subjects) [30]. The study by Sawada reported the effect of zinc supplementation compared to 149 
multivitamins, thus, they were not included in the meta-analysis of RCTs [54]. Finally, eight RCT 150 
studies were included in the final analysis (Table 2). The non-linear dose-response analysis failed 151 
to detect any significant effect of participant’s age on depression score (P-nonlinearity= 0.721) 152 
(Supplemental Figure 3), although there was a non-linear trend between baseline mood status on 153 
depression score in patients with mild to moderate depression (20-30 score) (Supplemental 154 
Figure 4). 155 
Observational studies: Studies were published between 2012 and 2020,  nine of which followed 156 
a cross-sectional design [38, 41, 40, 42, 43, 45-47, 49]; two were carried out in the USA [45, 46], 157 
five in Asia [38, 47, 40, 41, 49], one in Germany [43], and one in Australia [42]. From four 158 
prospective cohort studies, three studies were conducted in Australia [39, 48], and one in Finland 159 
[44]. The number of subjects and ages surveyed in the cross-sectional and prospective cohort 160 
studies ranged from 297 to 14834 (age: <18-79 years), and from 1705 to 9738 (age: from <18 to 161 
≥70 year), respectively (Table 1).  162 
Finding’s from RCTs.  The seven meta-analyzed RCTs indicated a significantly greater 163 
reduction in depression score with the zinc supplementation than with the control diets [weighted 164 
mean difference (WMD = −4.15 point; 95% CI: −6.56, −1.75 point; P < 0.01)] (19, 20, 30, 31, 165 
44-47), with substantial heterogeneity between studies (I2 = 80.1%; P-heterogeneity 166 
<0.001)(Figure 1). Subgroup analyses revealed that zinc supplementation significantly reduced 167 
depression scores in depressive patients who received zinc supplementation in the absence of 168 
anti-depressant medications (Table 3). The results of four models of meta-regression are 169 
presented in Table 4. Age, dose of zinc supplementation, study duration, and baseline depression 170 
score, in each study, were negatively associated with WMD for absolute change of depression 171 
score.  172 
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The omission of each study, individually, from the meta-analysis did not alter the overall effects. 173 
In addition, the Egger’s linear regression tests (P=0.393) and Begg’s test (P=0.368) did not 174 
indicate evidence for potential publication bias (Supplementary Figure 5). 175 
Findings from prospective cohort studies. Four cohort studies (15852 Participants, 2243 176 
incidence of depression) investigated the association between high versus low zinc intake and 177 
risk of depression [39, 44, 48]. The highest level of zinc intake was associated with a 28% 178 
reduced risk of depression (RR: 0.66; 95% CI: 0.50, 0.82; I2 = 13.90%; P-heterogeneity= 0.323) 179 
(Figure 2). 180 
Findings from cross-sectional studies. Overall, combining effect sizes from 9 studies [38, 41, 181 
40, 42, 43, 45-47, 49], that included 27296 participants and 3646 cases of depressive patients, 182 
revealed that high zinc status (a combination of dietary zinc and serum zinc concentration) was 183 
inversely associated with risk of depression (RR: 0.61; 95% CI: 0.51, 0.70) (Figure 3), with a 184 
low between-study heterogeneity (I2 = 0.0 %, P = 0.420). 185 
Study quality  186 
Based on the Cochrane tools used, the seven RCTs presented high methodologic quality [19, 20, 187 
52, 51, 53, 30, 31] (Supplementary Table 2). All cohort studies were recorded to have good 188 
quality [39, 44, 48] (Supplementary Table 3). In the cross-sectional studies, four studies were 189 
good [42, 43, 45, 41], however the remaining studies were scored as moderate to low quality [38, 190 
46, 47, 40, 49] (Supplementary Table 4). 191 
  192 
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Discussion:  193 
The present systematic review and meta-analysis of observational and RCTs studies sought to 194 
explicate the impact of zinc status and supplementation on depression development and treatment. 195 
First, our meta-analysis of cross-sectional studies revealed that inadequate zinc status (a 196 
combination of dietary zinc and serum zinc concentration) is prevalent among depressed patients. 197 
Second, we found that the highest level of zinc intake was associated with a 28% reduced risk of 198 
depression in the analysis of prospective cohort studies. Third, the result of the RCTs analysis 199 
confirmed the findings from observational studies regarding lower levels of zinc in depressed 200 
patients, and highlighted that zinc supplementation can significantly reduce depression score in 201 
depressive patients, when supplementing with zinc, in the absence of anti-depressant medications 202 
(monotherapy). Finally, this meta-analysis showed zinc supplementation had a beneficial effect on 203 
depression symptoms in patients with a depression score of 20-30 (mild to moderate depression).   204 
Findings from the present updated meta-analysis are in line with the previous meta-analysis that 205 
shows an inverse association between zinc status and risk of depression [22, 21], the potential to 206 
alleviate depression symptoms following zinc supplementation, and, adding to previous studies, 207 
that only zinc monotherapy significantly affected depression score. Furthermore, based on the 208 
current meta-analysis, the largest antidepressant effect of zinc supplementation was reported in 209 
mild to moderately depressed subjects.  210 
Micronutrient deficiencies are reported to be more frequent in depressed patients compared to 211 
healthy individuals [45, 55] . Indeed, deficiencies in key vitamins and minerals can interrupt the 212 
brain functioning and increase levels of stress. Zinc is one of the most important micronutrients, 213 
and plays a major role in the ability to regulate biological and psychological factors, and its 214 
inextricable association with depression has received much attention in field of nutrition and 215 
psychology in contemporary research   . Zinc deficiency is known to increase Reactive Oxygen 216 
Species (ROS) and oxidative stress, and both are involved in the physiopathology of depression 217 
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[55, 56, 15]. Second, it is accepted that synaptic zinc is an N-methyl-D-aspartate (NMDA) receptor 218 
antagonist [57, 58]; indeed, NMDA antagonists were found to be therapeutically targeted in studies 219 
of depression treatment [55, 59]. Further, according to animal-based investigations, blockade of 220 
NMDA receptors can eliminate the beneficial effects of zinc on depressive related symptoms, 221 
suggesting that NMDA receptors are a mediator of the antidepressant properties of zinc [60]. 222 
Furthermore, the effect on hormonal regulation, cortisol, cellular immune response [61], 223 
neurogenesis, neural plasticity, and expression of hippocampal and cortical brain-derived 224 
neurotrophic factor (BDNF) [30, 55] are considered as additive explanations for the beneficial 225 
effect of zinc in patients with depression. 226 
In the meta-regression models; age, dose of zinc supplementation, study duration, and baseline 227 
depression score made significant contributions to the change of depression. Indeed, higher doses 228 
of supplementation, longer intervention duration , and older adults with severe depression, 229 
respectively, were associated with an enhanced effect of zinc supplementation for decreasing 230 
depression score. However, due to the limited available evidence, these findings should be 231 
interpreted with caution 232 
This meta-analysis study included several lines of evidence; cross-sectional, prospective cohort, 233 
and intervention studies; which strongly support the zinc-depression relationship. While original 234 
[50, 19, 20] intervention studies have reported zinc may be efficacious as an adjunctive therapy 235 
for depression, our study revealed that mood-enhancing properties of zinc supplementation can be 236 
observed in depressed patients who supplement with zinc in the absence of anti-depressant 237 
medications (zinc monotherapy). This is important, because, while prescribers continue 238 
antidepressant therapy, early antidepressant discontinuation is widespread in the community of 239 
depressed patients [62]; in addition, relapses are prevalent and costly to healthcare systems [62, 240 
63].  241 
11 
 
A strength of the present meta-analysis is that it was the first to examine the effect of zinc 242 
monotherapy compared to placebo in depressed patients in RCTs. In addition, the dose–response 243 
relationship between zinc supplementation on depression status was in investigated, albeit a 244 
limited number of studies were eligible for analysis. However, in addition to the strengths and 245 
novelty of the present meta-analysis, there are some limitations that should be considered. 246 
Regarding the cohort studies, most included cohort studies in this meta-analysis had adjusted for 247 
potential confounders, including age, gender, socioeconomic status, BMI, physical activity, 248 
smoking status, but only two studies had adjusted for other micronutrients, including vitamin B 249 
family and vitamin D intake, as a confounder of risk of depression development [43, 47]. The 250 
different confounder adjustments among studies may lead to bias of the pooled results. Dietary 251 
zinc intake has been the main method for zinc status evaluation in observational studies, which is 252 
prone to measurement errors in zinc status assessment. Inconsistent criteria were used to 253 
diagnose depression among the observational studies included in the meta-analysis, which 254 
conceivably could have affected the strength of the association between zinc status and 255 
depression status.  256 
Regarding RCTs, we are not aware of an intervention study to have examined the effect of zinc 257 
supplementation on healthy subjects, and our results may, therefore, not be generalizable to a 258 
healthy population. Furthermore, in the present analysis, the number of eligible studies was small; 259 
however, comparatively, the previous meta-analysis in this field was conducted in fewer trials. 260 
The Beck depression scale used to determine depression status in all included studies; however, 261 
various thresholds in Beck scale criteria to categorize depression were applied in the RCTs; hence, 262 
it was difficult to distinguish the true effect of zinc supplementation on the severity of depression.  263 
All of the eligible RCTs followed their participants for less than six months, therefore, whether 264 
the effect of zinc supplementation persists for a longer period of time remains unknown, and 265 
therein represents a viable avenue for further research. An important limitation present in most of 266 
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the included studies was that they were conducted in a relatively low range of geographical 267 
locations (3 from 4 cohort studies established in Australia [39, 48], and 6 from 8 RCTs conducted 268 
in Iran[20, 52, 51, 30, 31]), thus, the association between zinc status and risk of depression may 269 
not be congruent in different populations, and clearly warrants further investigation. Although we 270 
conducted several subgroup analyses, we were unable to adequately detect the sources of 271 
heterogeneity. 272 
In conclusion, our findings advocate the preventative and therapeutic effect of zinc, compared to 273 
traditional antidepressant therapy, as a cost-efficient, efficacious, alternative approach. Future 274 
studies are needed to elucidate the effects of zinc intake on the depression-related symptoms in 275 
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Legend of Tables 443 
Table 1- Characteristics of observational studies evaluating the zinc-depression association 444 
 445 
Table 2- Characteristics of randomized controlled trials evaluating the effect of zinc 446 
supplementation on depression status. 447 
 448 
Table 3- Meta-analysis showing the effect of zinc supplementation on depression score based on 449 
several subgroups; all analyses were conducted using the random-effects model 450 
Table 4- Effect of zinc supplementation on weighted mean difference controlling for age, 451 
baseline depression score, dose of zinc supplementation and the study duration (conducted for 452 



























60 Dietary zinc 
intake 
SCID-I/NP2 0.24 (0.08, 0.76) Age, socioeconomic factors, physical activity, alcohol 






Cross-sectional 1514 (<18) 
 
 
238 Plasma Zinc CES-D4 0.67 (0.46, 0.97) Sex, age, and body mass index, hypothyroidism, serum vitamin 
D3and vitamin B12, plasma CRP, cognitive impairment, poor 


















0.94 (0.52, 1.69) Age, baseline depression severity, smoking, 







1367 Dietary zinc 
intake 
PHQ-98 0.70 (0.47, 1.04) Age, gender, BMI, race, educational level, smoking status, 
family income, work activity, recreational activity, hypertension, 










753 Dietary zinc 
intake 
CES-D 0.72 (0.52, 0.93) Age, race/ethnicity, socioeconomic status, BMI, physical 
activity, smoking status, total energy intake, any 








Cross-sectional 2006 (41) 
 
 






0.63 (0.45, 0.87) Age, sex, and site, marital status, job grade, shift work, physical 
activity, smoking, alcohol consumption, intake of folate and 









2092 (<18) 270 Dietary zinc 
intake 
CES-D 0.73 (0.44, 1.19) Education, household income, hypertension, BMI, 

















0.50 (0.30, 0.84) Sex, age, BMI, monthly expenses, close friends, living on 







cohort  (3) 
1705 (≥70) 83 Dietary zinc 
intake 
GDS 0.41 (0.20, 0.85) Age, body mass index, marital status, living arrangement, 
income, meal service, smoking, alcohol intake, comorbidity and 





Cross-sectional 297 (64) 125 Serum/dietary 
zinc 
GDS 1.26 (0.62, 2.34) age, BMI, sex, CVD, marital status, smoking, status, education, 
















0.6 (0.32, 1.12) age and sex, smoking, alcohol drinking, body mass index, shift 
work, and intake of Vitamin C, B6, B12, folic acid, and PUFA; 
 medications for hypertension, hyperlipidemia, and diabetes 
20 
 
1 Geelong Osteoporosis Study; 2 Structured Clinical Interview for DSM-IV-TR Research Version Non-patient edition; 3 Berlin Aging Study II; 4 Center for Epidemiological 
Studies Depression scale; 5 Kuopio Ischemic Heart Disease Risk Factor Study; 6 Human Population Laboratory Depression Scale; 7 National Health and Nutrition 
Examination Survey; 8 Patient Health Questionnaire; 9 Boston Area Community Health Survey; 10 Furukawa Nutrition and Health Study; 11 Hunter Community Study; 12 





Cross-sectional 1423 (≥65) 280 Dietary zinc 
intake 
GDS 0.58 (0.38, 0.9) age, BMI, living status, having a job status, married status, smoking status, 




Table 2- Characteristics of randomized controlled trials evaluating the effect of zinc supplementation on depression status. 
The first author 
(year) 
 


























Significant effect on Beck score in in combination 











BDI II  
Zinc (25) Anti-depressant 
drug 
Significant effect on Beck and HDS score in patients 












Significant effect on Beck score together with the 
antidepressant drug in patients with major depression 
 
Ranjbar, (2014 ) 
[52] 








Significant effect on HDRS score together with 
antidepressant drug in patients with major depression 
 
Salari, (2015 ) 
[51] 




12 BDI II  Zinc sulfate 
(220) 









12 HDRS, BDI 






No significant effect in antidepressant treatment 
nonresistant patients, significant effect in 




Iran Int:22, Cont:24 
(Both) 
Parallel Both 12  BDI II  Zinc gluconate 
(30) 








12  BDI II  Zinc gluconate 
(30) 
Placebo Significant effect on Beck score in depressed patients 






Table 3- Meta-analysis showing the effect of zinc supplementation on depression score based on several subgroups; all analyses were conducted 









P  between 
group 
Overall 7 -4.15 (-6.56, -1.75) <0.001 30.11 <0.001 80.1 -- 
        
Depression status        
Depressed patients 6 -4.58 (-7.55, -1.60)         0.003 30.06 <0.001 83.4 0.816 
Mixed population 1 -2.92 (-5.39, -0.44) 0.021 0.00 -- --  
        
Depression scale        
Beck 7 -4.16 (-6.56, -1.75) <0.001 30.11 <0.001 80.1 0.949 
Hamilton 3 -8.04 (-15.00, -1.07) 0.024 20.99 <0.001 90.5  
        
Duration        
Shorter period (≤ 12 weeks) 6 -4.73 (-8.25, -1.19) 0.009 29.99 <0.001 83.3 0.728 
Longer period (> 12 weeks) 1 -3.32 (-4.40, -2.24) <0.001 0.00 -- --  
        
zinc prescription        
Monotherapy 3 -5.05 (-7.55, -2.54) <0.001 4.35 0.114 54 0.024 
Adjunctive therapy 4 -3.70 (-7.80, 0.39) 0.076 20.66 <0.001 85.5  
        
Control group status        
Without antidepressant 3 -5.05 (-7.55, -2.54) <0.001 4.35 0.114 54 0.024 




Table 4- Effect of zinc supplementation on weighted mean difference controlling for age, baseline depression score, dose of zinc supplementation and the study 
duration (conducted for the random-effects model) 
Variable Estimated coefficient Standard error I-squared residual P- Value 
Age -0.134 0.037 83.50 0.005 
Zinc supplementation dose (mg/d) -0.178 0.049 80.95 0.006 
Duration (weeks) -0.321 0.116 85..28 0.015 




Legend of Figures 1 
Figure 1- Effect of zinc supplementation on depression status in randomized controlled trials  2 
Figure 2- Relative risk (RR) of depression status for the highest versus lowest category of zinc 3 
intake among prospective cohort studies. 4 
Figure 3- Relative risk (RR) of depression status for the highest versus lowest category of zinc 5 
status among cross-sectional studies. 6 
























Figure 2- Relative risk (RR) of depression status for the highest versus lowest category of zinc 28 
intake among prospective cohort studies. 29 




Figure 3- Relative risk (RR) of depression status for the highest versus lowest category of zinc 33 
status among cross-sectional studies. 34 
 35 
